{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:30:11Z","timestamp":1754109011411,"version":"3.37.3"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Sant\u00e9 Publique France"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>HIV-1 group O (HIV-1\/O) is one of the four HIV-1 groups and is endemic in Cameroon, representing 1% of HIV-1 infections in the population. Around 50% of the strains of this group naturally show a mutation (Y181C) providing them with resistance to NNRTIs and making therapeutic management more difficult. Today, the WHO recommends the use of integrase strand transfer inhibitors (INSTIs) as first-line treatment. Bictegravir and cabotegravir are the two most recent INSTIs. Because of the genetic polymorphism of HIV-1\/O, studies are required to evaluate their phenotypic susceptibility to these two drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>We performed a phenotypic study on a large panel including 41 HIV-1\/O clinical isolates and other rare non-group M HIV-1 (2 HIV-1\/N and 1 HIV-1\/P) to evaluate in vitro susceptibility to bictegravir and cabotegravir.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The results showed an overall susceptibility of non-group M strains to the two drugs compared with HIV-1 group M. There was no difference between the mean (min\u2013max) IC50 of HIV-1\/M [1.86\u2009(0.93\u20134.12) and 5.24 (1.76\u201312.41)\u2009nM for bictegravir and cabotegravir, respectively] and HIV-1\/non-M [2.17\u2009(0.03\u20139.47) and 4.88 (0.02\u201315.64)\u2009nM for bictegravir and cabotegravir, respectively]. However, we found a significant difference between IC50 values for bictegravir and cabotegravir in the whole panel (P value &amp;lt;\u200a0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study has shown encouraging results regarding the clinical use of these drugs in HIV-1\/non-M-infected patients, which will need to be confirmed with clinical data.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab196","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T20:02:25Z","timestamp":1622577745000},"page":"2306-2309","source":"Crossref","is-referenced-by-count":8,"title":["HIV-1 non-group M phenotypic susceptibility <i>in vitro<\/i> to bictegravir and cabotegravir"],"prefix":"10.1093","volume":"76","author":[{"given":"Charl\u00e8ne","family":"Martin","sequence":"first","affiliation":[{"name":"Normandie Univ, UNIROUEN, EA2656, GRAM 2.0, CHU de Rouen, Laboratoire de Virologie associ\u00e9 au CNR du VIH, F-76000, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9gol\u00e8ne","family":"Gracias","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNIROUEN, EA2656, GRAM 2.0, CHU de Rouen, Laboratoire de Virologie associ\u00e9 au CNR du VIH, F-76000, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9017-4941","authenticated-orcid":false,"given":"Quentin","family":"Le Hingrat","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-4083","authenticated-orcid":false,"given":"Jean-Christophe","family":"Plantier","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNIROUEN, EA2656, GRAM 2.0, CHU de Rouen, Laboratoire de Virologie associ\u00e9 au CNR du VIH, F-76000, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-3416","authenticated-orcid":false,"given":"Elodie","family":"Alessandri-Gradt","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNIROUEN, EA2656, GRAM 2.0, CHU de Rouen, Laboratoire de Virologie associ\u00e9 au CNR du VIH, F-76000, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"2021081309084485300_dkab196-B1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QAI.0000000000002246","article-title":"Brief report: complete genome sequence of CG-0018a-01 establishes HIV-1 subtype L","volume":"83","author":"Yamaguchi","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021081309084485300_dkab196-B2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/17130","article-title":"Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes","volume":"397","author":"Gao","year":"1999","journal-title":"Nature"},{"key":"2021081309084485300_dkab196-B3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1128\/CMR.00012-13","article-title":"Non-M variants of human immunodeficiency virus type 1","volume":"26","author":"Mourez","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2021081309084485300_dkab196-B4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.meegid.2015.09.006","article-title":"HIV-1 group O infection in Cameroon from 2006 to 2013: prevalence, genetic diversity, evolution and public health challenges","volume":"36","author":"Villabona-Arenas","year":"2015","journal-title":"Infect Genet Evol"},{"key":"2021081309084485300_dkab196-B5","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.1128\/jvi.71.11.8893-8898.1997","article-title":"Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses","volume":"71","author":"Descamps","year":"1997","journal-title":"J Virol"},{"key":"2021081309084485300_dkab196-B6","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/jac\/dkx190","article-title":"HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors","volume":"72","author":"Alessandri-Gradt","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021081309084485300_dkab196-B7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0923-2516(06)80097-X","article-title":"HIV1 sensitivity to zidovudine: need for phenotypic analysis. French Antiretroviral Drug Resistance Working Group","volume":"143","author":"Brun-V\u00e9zinet","year":"1992","journal-title":"Res Virol"},{"key":"2021081309084485300_dkab196-B8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1128\/JCM.05669-11","article-title":"A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection","volume":"50","author":"Gueudin","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2021081309084485300_dkab196-B9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/QAI.0000000000001003","article-title":"Performance evaluation of the new HIV-1 quantification assay, Xpert HIV-1 viral load, on a wide panel of HIV-1 variants","volume":"72","author":"Gueudin","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021081309084485300_dkab196-B10","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081309084485300_dkab196-B11","volume-title":"Antiretroviral Resistance in Clinical Practice","author":"Perno","year":"2006","edition":"ed"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/9\/2306\/39711636\/dkab196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/9\/2306\/39711636\/dkab196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T09:12:18Z","timestamp":1628845938000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/9\/2306\/6307083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":11,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,6,21]]},"published-print":{"date-parts":[[2021,8,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab196","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,6,21]]}}}